Unique ID issued by UMIN | UMIN000013340 |
---|---|
Receipt number | R000015569 |
Scientific Title | Prospective interventional study on safety of carbon ion radiotherapy and image-guided brachytherapy for locally advanced uterine cervical cancer (GUNMA1202) |
Date of disclosure of the study information | 2014/03/05 |
Last modified on | 2021/06/08 14:39:57 |
Prospective interventional study on safety of carbon ion radiotherapy and image-guided brachytherapy for locally advanced uterine cervical cancer (GUNMA1202)
Prospective interventional study on safety of carbon ion radiotherapy and brachytherapy for uterine cervical cancer
Prospective interventional study on safety of carbon ion radiotherapy and image-guided brachytherapy for locally advanced uterine cervical cancer (GUNMA1202)
Prospective interventional study on safety of carbon ion radiotherapy and brachytherapy for uterine cervical cancer
Japan |
Locally advanced uterine cervical cancer
Obstetrics and Gynecology | Radiology |
Malignancy
NO
To assess the safety of the concurrent therapy of carbon ion radiotherapy and image-guided brachytherapy for locally advanced uterince cervical cancer
Safety
1) Incidence of dose-limiting toxicity.
2) Incidence rate of acute adverse effects (within 90 days after the start of treatment).
1) Primary response in pelvis.
2) Incidence rate of late adverse effect (after 90 days from the start of treatment).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Device,equipment |
Carbon ion radiotherapy
Image-guided brachytherapy
Chemotherapy (Cisplatin)
20 | years-old | <= |
75 | years-old | >= |
Female
1) Histologically diagnosed adenocarcinoma, adeno-squamous cell carcinoma, or squamous cell carcinoma of uterine cervix.
2) FIGO Stage II (larger than or equal to 4 cm), III, or IV.
3) No para-aortic lymph node with the smaller diameter equal to or larger than 1 cm is observed in CT within 4 weeks before registration.
4) Measurable tumors on CT or MRI.
5) Age >=20 <=75.
6) Performance status 0-2.
7) No prior history of surgery or chemotherapy for uterine cervical cancer.
8) No abnormality in major organ functions.
9) Expected life expectancy of more than 6 months.
10) Informed consent is obtained.
1) Tumor invasion to gastro-intestinal tract.
2) Past history of chemotherapy.
3) Past history of radiotherapy in pelvis.
4) Uncontrolled infection in pelvis.
5) Severe concomitant diseases.
6) Active concurrent cancers.
7) (Possibly) pregnant patients.
8) Other medically or psychologically unsuitable circumstances are present.
6
1st name | |
Middle name | |
Last name | Takashi Nakano |
Gunma University
Gunma University Heavy Ion Medical Research Center
3-39-22 Showa-machi, Maebashi, Gunma
027-220-8378
tnakano@gunma-u.ac.jp
1st name | |
Middle name | |
Last name | Tatsuya Ohno |
Gunma University
Gunma University Heavy Ion Medical Research Center
3-39-22 Showa-machi, Maebashi, Gunma
027-220-8378
tohno@gunma-u.ac.jp
Gunma University Heavy Ion Medical Center
MEXT
NO
2014 | Year | 03 | Month | 05 | Day |
Unpublished
No longer recruiting
2013 | Year | 05 | Month | 31 | Day |
2013 | Year | 06 | Month | 01 | Day |
2014 | Year | 07 | Month | 01 | Day |
2014 | Year | 03 | Month | 05 | Day |
2021 | Year | 06 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015569
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |